Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 28

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 28
---
 to noncontrolling interests2 (5)Comprehensive income (loss) attributable to noncontrolling interests1 (6)Comprehensive income attributable to Boston Scientific common stockholders$372 $578 

Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding.

4

Table of Contents

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

 As of(in millions, except share and per share data)March 31, 2025December 31, 2024ASSETS  Current assets:  Cash and cash equivalents$725 $414 Trade accounts receivable, net2,693 2,558 Inventories2,867 2,810 Prepaid income taxes294 307 Other current assets756 831 Total current assets7,335 6,920 Property, plant and equipment, net3,389 3,294 Goodwill17,340 17,089 Other intangible assets, net6,566 6,684 Deferred tax assets3,676 3,655 Other long-term assets1,834 1,754 TOTAL ASSETS$40,140 $39,395 LIABILITIES AND STOCKHOLDERS’ EQUITY  Current liabilities:  Current debt obligations$777 $1,778 Accounts payable1,004 960 Accrued expenses2,354 2,773 Other current liabilities923 887 Total current liabilities5,058 6,399 Long-term debt10,532 8,968 Deferred tax liabilities158 155 Other long-term liabilities1,946 1,870 Commitments and contingenciesStockholders’ equity  Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of March 31, 2025 and December 31, 2024— — Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,742,488,328 shares as of March 31, 2025 and 1,737,846,196 shares as of December 31, 202417 17 Treasury stock, at cost - 263,289,848 shares as of March 31, 2025 and December 31,